Myelofibrosis Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Myelofibrosis remains an active clinical development field. The competitive center of gravity is moving toward biomarker-defined populations, rational combinations, earlier treatment lines and evidence that can survive active-comparator scrutiny. The PatSnap evidence set used here contains 165 matched trial records and 433 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| JPRN-jRCT2071260059 | Intervention not normalized | Phase 2; 募集前 | Sponsor not listed | Japan | 投与開始後36週時点において、ベースライン時と比較し骨髄線維化スコアが少なくとも1グレード以上低下した被験者の割合; Proportion of participants who achieved a reduction of at least one grade in bone marrow fibrosis score at Week 36 compared with baseline. | 2030-03-31 |
| CTR20262711 | Rovadicitinib | Phase 1; 进行中 （尚未招募） | Centaurus Biopharma Co Ltd; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Nanjing Shunxin Pharmaceutical Co., Ltd. | China | (给药后24小时) | Timing not listed |
| NCT07623161 | Elritercept | Phase 3; Not yet recruiting | Takeda Pharmaceutical Co., Ltd. | Geography not listed | Proportion of Participants Who Are Red Blood Cell-Transfusion Independent (RBC-TI) for Any Consecutive Greater Than or Equal to (≥) 12-Week Period During the 36-Week Double-Blinded Treatment Period (From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)) | 2029-12-07 |
| NCT07608666 | Rovadicitinib + Rabeprazole Sodium | Phase 1; Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | China | Peak concentration (Cmax) (1 hour before administration, and 10, 20 minutes, 0.5, 0.75, 1, 2, 3, 4, 6, 8,…); Area under the plasma concentration-time curve ( AUC0-t) (1 hour before administration, and 10, 20 minutes, 0.5, 0.75, 1, 2, 3, 4, 6, 8,…) | 2026-12-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study (Phase 1/2): the indexed record reports SV(reduction of ≥20%) = 26.0 %.
- A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis. (Phase 2): the indexed record reports -; -; -.
- SELINEXOR PLUS RUXOLITINIB IN JANUS KINSE INHIBITOR–NAÏVE MYELOFIBROSIS: PHASE 3 SENTRY TRIAL (Phase 3): the indexed record reports SVR35(Week 24) = 28.0 %; SVR35(Week 24) = 49.8 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Rovadicitinib (Approved; JAK1 x JAK2 x ROCK1 x ROCK2), Elritercept (Phase 3; ACVR2A), Rabeprazole Sodium (Approved; Proton pump). Company & Deal Intelligence records identify sponsor context for Centaurus Biopharma Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing Shunxin Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. (4502). Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Prospective biomarker thresholds that predict benefit rather than simply confirm target presence.
- Randomized sequencing evidence after prior targeted therapy, immunotherapy or antibody–drug conjugates.
- Endpoints that connect response depth with durability, quality of life and overall survival.
- Geographically broader development programs with harmonized molecular testing.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Myelofibrosis has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
